- Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases(2022)
Auteurs: Debby Thomas, Séverine Vermeire, Peter Bossuyt
Pagina's: 208 - 217
- Another gastrointestinal lesion amendable for ablation(2022)
Auteurs: Peter Bossuyt
Pagina's: 113 - 113
- Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study(2021)
Auteurs: Peter Bossuyt
Pagina's: 439 - 445
- Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (vol 158, pg 2139, 2020)(2021)
Auteurs: Erwin Dreesen, Séverine Vermeire, Peter Bossuyt
Pagina's: 817 - 817
- Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies(2021)
Auteurs: Peter Bossuyt, Marc Ferrante
Pagina's: S357 - S358
- The value of imaging and endoscopic scoring for the prediction of outcomes in inflammatory bowel disease: Towards objective and predictive outcome measures.(2021)
Auteurs: Peter Bossuyt, Séverine Vermeire, Raf Bisschops
- Is Also the Patient Ready for Switching from Intravenous to Subcutaneous Biologics?(2021)
Auteurs: Peter Bossuyt
Pagina's: 515 - 516
- Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial(2021)
Auteurs: Peter Bossuyt
Pagina's: 199 - 206
- International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease(2021)
Auteurs: Peter Bossuyt
Pagina's: 857 - 873
- High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial(2021)
Auteurs: Peter Bossuyt, Marc Ferrante
Pagina's: 1573 - +